Mesenchymal Stromal Cells for Degenerative Meniscus Injury
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02033525 |
Recruitment Status :
Completed
First Posted : January 10, 2014
Last Update Posted : January 9, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Meniscal Injury | Drug: XCEL-M-ALPHA and standard rehabilitation Other: Rehabilitation | Phase 1 Phase 2 |
This is a prospective, unicentric, randomized, open-label, single-dose, two-arm, blinded assessor pilot study in which 20 patients with degenerative meniscus injury grade 3 (Crues et al.) will enter the study with the primary objective of assessing the efficacy of the treatment by VAS of pain at 12 month. Secondary objectives are to evaluate the safety and efficacy through imaging procedures and clinical questionnaires (IKDC, KOOS, Lysholm and SF-36.
Patients will be randomized to one of the two treatment arms (XCEL-M-ALPHA and standard rehabilitation program or standard rehabilitation program alone). Thereafter, patients will be followed for 12 months.
Imaging assessment will be performed by an independent blinded radiologist.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury |
Actual Study Start Date : | January 31, 2014 |
Actual Primary Completion Date : | May 2, 2017 |
Actual Study Completion Date : | May 2, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: XCEL-M-ALPHA and standard rehabilitation
Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
|
Drug: XCEL-M-ALPHA and standard rehabilitation
Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
Other Name: XCEL-M-ALPHA |
Active Comparator: standard rehabilitation
Standard rehabilitation program
|
Other: Rehabilitation
Standard rehabilitation program |
- VAS for pain [ Time Frame: 12 month ]Visual analogue scale (VAS) for pain at 12 month follow-up.
- Safety [ Time Frame: 12 month ]Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.
- Efficacy by MRI [ Time Frame: 6 and 12 month ]Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.
- VAS for pain [ Time Frame: 1, 3 and 6 month ]Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.
- Efficacy by clinical questionnaires [ Time Frame: 3, 6 and 12 month ]IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient between 40 and 60 years of age
- Degenerative meniscus injury grade 3 (Crues et al.)
- Indication of conservative treatment
- Normal alignment of the knee (between 3º varus and 10 º valgus)
- Patient is able to follow a rehabilitation program
- Informed consent given by the patient in writing
- Patient is able to understand the trial.
Exclusion Criteria:
- Traumatic meniscus injury
- Surgical intervention to the affected knee
- Local or systemic infection
- Intraarticular treatment of the affected knee with steroids or hyaluronic acid within the past 3 months
- Significant abnormal laboratory tests that contraindicates participation in the trial.
- Pregnant women or intend to become pregnant or breast-feeding
- Neoplastic process within the previous 5 years or without complete remission.
- The patient is wearing a pacemaker, allergy to contrast, severe renal insufficiency or any other condition that contraindicates the magnetic resonance using contrast.
- Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
- Legally dependant patient.
- The patient does not accept to be followed-up for a period that could exceed the clinical trial length

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02033525
Spain | |
ICATME-Hospital Quiron Dexeus | |
Barcelona, Spain, 08028 |
Principal Investigator: | Joan Carles Monllau, MD, PhD | ICATME-Hospital Quiron Dexeus |
Responsible Party: | Banc de Sang i Teixits |
ClinicalTrials.gov Identifier: | NCT02033525 |
Other Study ID Numbers: |
XCEL-MEN-01 2011-006270-13 ( EudraCT Number ) |
First Posted: | January 10, 2014 Key Record Dates |
Last Update Posted: | January 9, 2018 |
Last Verified: | January 2018 |
Chronic Meniscal Injury Degenerative meniscus Meniscus injury Meniscal injury |
Mesenchymal stromal cells Mesenchymal stem cells Advanced Therapy Bone marrow |
Wounds and Injuries |